FDA issued a drug warning: be careful about the adverse effects of hepatitis C drugs on the heart

Recently, the FDA issued a drug warning: the use of sofibvir containing drugs combined with another direct antiviral drug for the treatment of hepatitis C, when the two are taken together with amiodarone, can cause serious cardiac arrest There are two kinds of drugs that have been listed, one is suofibuvir tablet, the trade name is sovaldi, the other is compound preparation, the trade name is harvoni, the active ingredient is laidipaver + suofibuvir, which are developed by Gilead technology company In a drug warning issued by the FDA, the use of harvoni or sovaldi in combination with another direct antiviral drug for the treatment of hepatitis C virus infection can cause serious arrhythmia when they are taken together with amiodarone, an antiarrhythmic drug The FDA is putting information about the adverse effect, symptomatic bradycardia, on the drug labels of harvoni and sovaldi FDA advises doctors not to take these two drugs with other direct antiviral drugs and amiodarone Other antiviral drugs, such as the new drug daclatasvir or olysio (simeprevir), are under study FDA reviewed the adverse reaction reports submitted after marketing and found that when harvoni or sovaldi was used in combination with another direct antiviral drug, and both of them were taken together with amiodarone, patients could have symptomatic bradycardia In the adverse reaction reports, one patient died of cardiac arrest, and three patients needed to put a pacemaker to regulate the heart rhythm Other patients recovered after discontinuation of hepatitis C drugs or amiodarone The cause of adverse reactions has not yet been identified FDA will continue to monitor the risk of serious cardiac arrest caused by the above two drugs, and find out the cause of heart disease caused by the combination of amiodarone and these hepatitis C drugs The FDA recommends that doctors should not combine these two drugs with another antiviral drug while using amiodarone However, if the alternative treatment is not feasible, the patient should be hospitalized for cardiac monitoring within 48 hours of the beginning of the treatment, and then, within 2 weeks of the beginning of the treatment, cardiac rhythm monitoring should be performed once a day Due to the long half-life of amiodarone, patients should also be monitored according to the above adverse reactions before stopping amiodarone and starting to take these two drugs and another direct antiviral drug Translation from FDA: http:// be the author's personal opinion, not the position of this website The intellectual property rights of the published content belong to yaozhi.com If you need to reprint, please indicate the source and the link of this article.